Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287410054> ?p ?o ?g. }
- W2287410054 endingPage "428" @default.
- W2287410054 startingPage "417" @default.
- W2287410054 abstract "Osteoporosis is a bone pathology leading to increased fracture risk and challenging the quality of life. As current treatments can exhibit deleterious side effects, the use of phyto-compounds with therapeutic and preventive activities against orthopaedic related problems represents a promising alternative. We investigated the effect of aloin, an anthrocyclic compound, on inhibition of osteoclastogenesis using receptor of the nuclear factor κB (NF-κB) ligand (RANKL)-induced RAW264.7 macrophage cells. The inhibitory effect of aloin on in vitro osteoclastogenesis was evaluated by reduction in tartrate-resistant acid phosphatase (TRAP) content and expression levels of osteoclast-specific gene, cathepsin K. Multinuclear formation of osteoclast was assessed with haematoxylin and eosin staining. F4/80 content the marker of the murine monocyte/macrophage cells, was evaluated by immunocytochemistry. The underlining mechanisms were assessed by Western blots and EMSA. Effect of aloin on generation of intracellular reactive oxygen species (ROS) was estimated by dichlorofluorescein diacetate (DCFH-DA). Bone degradation effect was evaluated by bone pit assay. The bone pit culture supernatant was studied by Fluorescein assay. We demonstrated that aloin reduced TRAP content and levels of osteoclast-specific gene and protein, cathepsin K. Treatment with aloin (0.75 µM) prevented multinuclear formation (haematoxylin and eosin staining), reduced intracellular TRAP content (TRAP Staining) and increased F4/80 content (F4/80 immunohistochemistry) in RANKL (20 ng/ml) treated RAW cells. Treatment of the RAW cells with aloin suppressed RANKL-induced NF-κB pathway components like IKKα, IKKβ, Phospho.IKK α/β, NF-κB-p65, Phospho NF-κB-p65 and IκBα. EMSA studies showed aloin dose dependently reduced DNA binding activity of NF-κB. Additionally, in vitro bone pit assay revealed that aloin prevented bone degradation and also decreased the fluorescence content in cells, thus confirming the role of aloin in inhibition of osteoclastogenesis . Collectively, this study identifies aloin as a potent inhibitor of osteoclastogenesis and bone resorption. The action of aloin was in par with alendronate sodium trihydrate and may provide evidence for its therapeutic potential to treat diseases involving abnormal bone lysis." @default.
- W2287410054 created "2016-06-24" @default.
- W2287410054 creator A5006296502 @default.
- W2287410054 creator A5006511162 @default.
- W2287410054 creator A5015734350 @default.
- W2287410054 creator A5022075915 @default.
- W2287410054 creator A5038170170 @default.
- W2287410054 creator A5041837959 @default.
- W2287410054 date "2016-04-01" @default.
- W2287410054 modified "2023-09-27" @default.
- W2287410054 title "NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells" @default.
- W2287410054 cites W1967502057 @default.
- W2287410054 cites W1972001482 @default.
- W2287410054 cites W1973142147 @default.
- W2287410054 cites W1985302646 @default.
- W2287410054 cites W1991460671 @default.
- W2287410054 cites W1994403682 @default.
- W2287410054 cites W1995975385 @default.
- W2287410054 cites W2002165948 @default.
- W2287410054 cites W2017884068 @default.
- W2287410054 cites W2025508536 @default.
- W2287410054 cites W2027791116 @default.
- W2287410054 cites W2029264336 @default.
- W2287410054 cites W2044652433 @default.
- W2287410054 cites W2057935861 @default.
- W2287410054 cites W2064346787 @default.
- W2287410054 cites W2072510816 @default.
- W2287410054 cites W2073472143 @default.
- W2287410054 cites W2085536927 @default.
- W2287410054 cites W2093252878 @default.
- W2287410054 cites W2098085126 @default.
- W2287410054 cites W2132408993 @default.
- W2287410054 cites W2134230637 @default.
- W2287410054 cites W2134457900 @default.
- W2287410054 cites W2143563671 @default.
- W2287410054 cites W2157942810 @default.
- W2287410054 cites W2170474771 @default.
- W2287410054 cites W2197016826 @default.
- W2287410054 cites W2319741803 @default.
- W2287410054 doi "https://doi.org/10.1016/j.phymed.2016.01.006" @default.
- W2287410054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27002412" @default.
- W2287410054 hasPublicationYear "2016" @default.
- W2287410054 type Work @default.
- W2287410054 sameAs 2287410054 @default.
- W2287410054 citedByCount "26" @default.
- W2287410054 countsByYear W22874100542017 @default.
- W2287410054 countsByYear W22874100542018 @default.
- W2287410054 countsByYear W22874100542019 @default.
- W2287410054 countsByYear W22874100542020 @default.
- W2287410054 countsByYear W22874100542021 @default.
- W2287410054 countsByYear W22874100542022 @default.
- W2287410054 countsByYear W22874100542023 @default.
- W2287410054 crossrefType "journal-article" @default.
- W2287410054 hasAuthorship W2287410054A5006296502 @default.
- W2287410054 hasAuthorship W2287410054A5006511162 @default.
- W2287410054 hasAuthorship W2287410054A5015734350 @default.
- W2287410054 hasAuthorship W2287410054A5022075915 @default.
- W2287410054 hasAuthorship W2287410054A5038170170 @default.
- W2287410054 hasAuthorship W2287410054A5041837959 @default.
- W2287410054 hasConcept C101990758 @default.
- W2287410054 hasConcept C142724271 @default.
- W2287410054 hasConcept C153911025 @default.
- W2287410054 hasConcept C170493617 @default.
- W2287410054 hasConcept C180675623 @default.
- W2287410054 hasConcept C185592680 @default.
- W2287410054 hasConcept C190283241 @default.
- W2287410054 hasConcept C202751555 @default.
- W2287410054 hasConcept C2776033226 @default.
- W2287410054 hasConcept C2776919888 @default.
- W2287410054 hasConcept C2777730290 @default.
- W2287410054 hasConcept C2779428903 @default.
- W2287410054 hasConcept C55493867 @default.
- W2287410054 hasConcept C71924100 @default.
- W2287410054 hasConcept C74864618 @default.
- W2287410054 hasConcept C86803240 @default.
- W2287410054 hasConcept C88045685 @default.
- W2287410054 hasConceptScore W2287410054C101990758 @default.
- W2287410054 hasConceptScore W2287410054C142724271 @default.
- W2287410054 hasConceptScore W2287410054C153911025 @default.
- W2287410054 hasConceptScore W2287410054C170493617 @default.
- W2287410054 hasConceptScore W2287410054C180675623 @default.
- W2287410054 hasConceptScore W2287410054C185592680 @default.
- W2287410054 hasConceptScore W2287410054C190283241 @default.
- W2287410054 hasConceptScore W2287410054C202751555 @default.
- W2287410054 hasConceptScore W2287410054C2776033226 @default.
- W2287410054 hasConceptScore W2287410054C2776919888 @default.
- W2287410054 hasConceptScore W2287410054C2777730290 @default.
- W2287410054 hasConceptScore W2287410054C2779428903 @default.
- W2287410054 hasConceptScore W2287410054C55493867 @default.
- W2287410054 hasConceptScore W2287410054C71924100 @default.
- W2287410054 hasConceptScore W2287410054C74864618 @default.
- W2287410054 hasConceptScore W2287410054C86803240 @default.
- W2287410054 hasConceptScore W2287410054C88045685 @default.
- W2287410054 hasIssue "4" @default.
- W2287410054 hasLocation W22874100541 @default.
- W2287410054 hasLocation W22874100542 @default.
- W2287410054 hasOpenAccess W2287410054 @default.
- W2287410054 hasPrimaryLocation W22874100541 @default.